Please use this identifier to cite or link to this item: http://adhlui.com.ui.edu.ng/jspui/handle/123456789/2379
Full metadata record
DC FieldValueLanguage
dc.contributor.authorABDURRAHMAN, M.B-
dc.contributor.authorTAQI, A.M-
dc.date.accessioned2024-07-24T10:17:04Z-
dc.date.available2024-07-24T10:17:04Z-
dc.date.issued1981-
dc.identifier.citationAfr. J. Med Med. Sci. (1981) 10:57-62.en_US
dc.identifier.issn1116-4077-
dc.identifier.urihttp://adhlui.com.ui.edu.ng/jspui/handle/123456789/2379-
dc.descriptionArticleen_US
dc.description.abstractAlthough an effective vaccine against measles has been available for several years, the disease is still prevalent in Africa . The disease is characterized by its occurrence in younger age groups and high morbidity and mortality. The African child is born with a high transplacental^ acquired measles antibody level. However, the antibody declines rapidly, so that it is virtually absent after the age of 6 months. The measles vaccine with which the African child is immunized is of reduced potency because of poor storage and transportation facilities and the adverse effect of tropical climate on the vaccine. The pattern of measles immunity in Africa is different from that in developed countries. Measles immunization schedule in Africa, as in any other part of the world, must be based on sound epidemiological and serological data .en_US
dc.description.sponsorshipCOLLEGE OF MEDICINEen_US
dc.language.isoenen_US
dc.publisherBLACKWELL SCIENTIFIC PUBLICATIONSen_US
dc.subjectvaccineen_US
dc.subjectmeaslesen_US
dc.subjectAfricaen_US
dc.subjectimmunization scheduleen_US
dc.titleMEASLES IMMUNITY AND IMMUNIZATION IN DEVELOPING COUNTRIES OF AFRICA : A REVIEWen_US
dc.typeArticleen_US
Appears in Collections:African Journal of Medicine and Medical Sciences

Files in This Item:
File Description SizeFormat 
Abdurrahman_Taqi_Measles_1981.pdfArticle11.02 MBAdobe PDFView/Open


Items in COMUI (ADHL) are protected by copyright, with all rights reserved, unless otherwise indicated.